← daily scanner dashboard

#3 KRYS — Krystal Biotech, Inc.

B_VCP_DEVELOPING | as of 2026-09-25 | automated relative priority, not a published Minervini point formula

Relative priority64.17
RS rating89.45
Fundamental strength75.00
VCP score90.48
Pivot distance4.55%
AV confirmation80.00%complete
Technical chart for KRYS

Trend Template

price_above_sma150_and_sma200PASS
sma150_above_sma200PASS
sma200_rising_1mPASS
sma50_above_sma150_and_sma200PASS
price_above_sma50PASS
price_at_least_30pct_above_52w_lowPASS
price_within_25pct_of_52w_highPASS
rs_rating_at_least_70PASS

Trend Template metrics

close345.82
sma50343.43
sma150311.04
sma200299.18
sma200_1m_ago283.97
pct_above_52w_low118.76
pct_below_52w_high9.60
rs_rating89.45

VCP conditions

coherent_contraction_sequencePASS
enough_contractionsPASS
successive_ranges_inside_firstPASS
successive_depths_contractingPASS
final_contraction_tightPASS
base_depth_okPASS
resistance_area_tightPASS
volume_dryupFAIL
atr_contractingPASS
price_tightPASS
near_pivotPASS

VCP metrics

num_contractions2.00
contraction_depths_pct[11.12, 8.53]
depth_ratios_vs_prior[0.767]
target_depth_ratio_roughly_half0.50
max_allowed_depth_ratio0.80
base_high373.31
base_low331.80
base_depth_pct11.12
base_duration_weeks3.10
resistance_spread_pct2.95
volume_dryup_ratio_10d_vs_50d0.79
atr_pct_recent3.34
atr_pct_prior4.18
atr_contraction_ratio0.80
tight_10d_range_pct9.33
raw_contraction_count11.00
raw_depths_pct[7.28, 10.54, 10.48, 9.67, 14.26, 9.97, 19.51, 4.66, 5.13, 11.12, 8.53]
final_trough_age_bars3.00
selection_reasoncoherent_current_sequence
pivot_price362.30
distance_to_pivot_pct4.55
vcp_score_pct90.48
is_vcp_candidatePASS
breakout_on_volumeFAIL

Price / volume

return_1m_pct-3.87
return_3m_pct-7.10
return_6m_pct37.56
return_12m_pct113.47
weighted_12m_momentum17.90
range_10d_pct9.33
range_20d_pct12.65
avg_volume_50d393,535
dollar_volume_50d136.09M
up_down_volume_ratio_50d0.54
accumulation_days_20d2.00
distribution_days_20d3.00

Fundamental overlay criteria

eps_growth_minimumPASS
sales_growth_positive_or_betterPASS
core_data_coveragePASS
eps_acceleratingFAIL
sales_acceleratingFAIL
gross_margin_improving—
operating_margin_improvingPASS

Minervini-oriented SEC fundamentals

eps_growth_yoy_pct38.76
eps_previous_q_yoy_growth_pct52.50
eps_acceleration_pts-13.74
eps_annual_growth_pct128.00
eps_cagr_3y_pct—
sales_growth_yoy_pct24.14
sales_previous_q_yoy_growth_pct31.95
sales_acceleration_pts-7.81
sales_annual_growth_pct33.95
sales_cagr_3y_pct—
gross_margin_pct—
operating_margin_pct49.00
pretax_margin_pct55.42
net_margin_pct45.94
gross_margin_yoy_change_pts—
operating_margin_yoy_change_pts7.98
roe_latest_fy_pct18.91
current_ratio8.32
debt_to_equity_pct—
cash_to_debt—
shares_outstanding—
adjusted_eps_growth_yoy_pct—
earnings_surprise_pct—
eps_estimate_revision_30d_pct—
analyst_count—
institutional_ownership_pct—
institutional_qoq_change_pct—
management_guidance_revision_pct—

SEC data quality

core_coverage_pct90.00
missing_core_metrics["shares_outstanding"]
selected_sec_tags{"accounts_payable": "us-gaap:AccountsPayableCurrent", "accounts_receivable": "us-gaap:AccountsReceivableNetCurrent", "capex": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "cash": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "cost_of_revenue": null, "current_assets": "us-gaap:AssetsCurrent", "current_liabilities": "us-gaap:LiabilitiesCurrent", "dividends_paid": null, "eps_basic": "us-gaap:EarningsPerShareBasic", "eps_diluted": "us-gaap:EarningsPerShareDiluted", "equity": "us-gaap:StockholdersEquity", "gross_profit": null, "inventory": "us-gaap:InventoryNet", "long_term_debt": null, "long_term_debt_current": null, "net_income": "us-gaap:NetIncomeLoss", "operating_cash_flow": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "operating_income": "us-gaap:OperatingIncomeLoss", "pretax_income": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "r_and_d": "us-gaap:ResearchAndDevelopmentExpense", "revenue": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "sga": "us-gaap:SellingGeneralAndAdministrativeExpense", "share_repurchases": null, "shares_outstanding": "dei:EntityCommonStockSharesOutstanding", "short_term_debt": null, "short_term_investments": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "stock_based_comp": "us-gaap:ShareBasedCompensation", "total_assets": "us-gaap:Assets", "total_liabilities": "us-gaap:Liabilities", "weighted_avg_diluted_shares": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"}
unavailable_canonical_concepts["cost_of_revenue", "dividends_paid", "gross_profit", "long_term_debt", "long_term_debt_current", "share_repurchases", "short_term_debt"]
warnings["Standalone Q4 income/EPS can be absent because 10-K statements are annual.", "Company-specific extension tags are not returned by CompanyFacts.", "Non-GAAP EPS, guidance, 13F ownership, Form 4 activity, and analyst estimates are separate modules."]

Reporting periods

latest_quarter_end2026-06-30
latest_quarter_filed2026-08-03
latest_fiscal_year_end2025-12-31
latest_balance_sheet_end2026-06-30

Company metadata

symbolKRYS
cik1.71M
company_nameKrystal Biotech, Inc.
exchange—
sic2,836
sic_descriptionBiological Products, (No Diagnostic Substances)
fiscal_year_end1,231
as_of2026-09-27
sourceSEC EDGAR CompanyFacts + Submissions

Alpha Vantage enrichment

latest_reported_date2026-08-03
latest_reported_eps1.79
latest_estimated_eps1.70
latest_earnings_surprise_pct5.29
avg_earnings_surprise_4q_pct44.82
positive_earnings_surprises_4q4.00
earnings_surprise_quarters_available4.00
reported_eps_yoy_growth_pct38.76
estimate_period2027-12-31
analyst_count_eps—
analyst_count_revenue—
eps_estimate_avg—
revenue_estimate_avg—
estimate_revision.eps_estimate_revision_up_trailing_7_days2.00
estimate_revision.eps_estimate_revision_up_trailing_30_days3.00
estimate_revision.eps_estimate_revision_down_trailing_30_days5.00
eps_revision_up_30d3.00
eps_revision_down_30d5.00
eps_revision_net_up_30d-2.00
institutional.total_institutional_holders469.00
institutional.total_institutional_shares33.39M
institutional.holders_with_increased_holdings274.00
institutional.holders_with_decreased_holdings152.00
institutional.holders_with_unchanged_holdings43.00
institutional_holder_rows469.00
institutional_total_shares33.39M
endpoints_returned["EARNINGS", "EARNINGS_ESTIMATES", "INSTITUTIONAL_HOLDINGS"]

Alpha Vantage confirmation screen

latest_earnings_surprise_positivePASS
average_4q_earnings_surprise_positivePASS
positive_surprise_quartersPASS
analyst_coverage_present—
eps_revision_breadth_nonnegative_30dFAIL
institutional_sponsorship_presentPASS

Alpha Vantage screen summary

statuscomplete
confirmation_score_pct80.00
available_criteria5.00
noteInformational post-Exp0 confirmation only; not part of validated Exp0 selection/ranking.

Alpha Vantage endpoint status

EARNINGScache_available
EARNINGS_ESTIMATEScache_available
INSTITUTIONAL_HOLDINGScache_available

Accepted VCP contractions

peak_datepeak_pricetrough_datetrough_pricedepth_pctdepth_ratio_vs_priorbars
2026-09-03373.312026-09-15331.8011.12—7.00
2026-09-22362.302026-09-22331.398.530.770.00

Recent SEC filings

formfiling_dateaccession_numberprimary_document
8-K2026-08-030001711279-26-000058krys-20260803.htm
10-Q2026-08-030001711279-26-000057krys-20260630.htm
8-K2026-07-210001711279-26-000050krys-20260721.htm
8-K2026-05-200001711279-26-000047krys-20260515.htm
8-K2026-05-040001711279-26-000044krys-20260504.htm
10-Q2026-05-040001711279-26-000043krys-20260331.htm
8-K2026-02-170001711279-26-000018krys-20260217.htm
10-K2026-02-170001711279-26-000016krys-20251231.htm
8-K2026-01-120001711279-26-000008krys-20260111.htm
8-K2026-01-080001711279-26-000005krys-20260108.htm
8-K2025-12-230001711279-25-000092krys-20251223.htm
8-K2025-11-030001711279-25-000088krys-20251103.htm

SEPA factors not covered by SEC + Yahoo

These remain manual or require another provider/module and are deliberately not guessed: